For 15 years, targeted therapy against BRAF(mutated in 50–60% of primary melanoma) or MEK protein has been developed, and some of these treatments have been commercialized, including BRAF inhibitors, such as vemurafenib (or PLX4032) and dabrafenib, and MEK inhibitors, such as cobimetinib, or trametinib (9). This evidence concerns the gene BRAF and melanoma.